The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Open accessAbstract
BACKGROUND: Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after coronary-artery bypass grafting (CABG). We conducted a randomized trial to assess the safety of these drugs after CABG. METHODS: In this randomized, double-blind study involving 10 days of treatment and 30 days of follow-up, 1671 patients were randomly assigned to receive intravenous parecoxib for at least 3 days, followed by oral valdecoxib through day 10; intravenous placebo followed by oral valdecoxib; or placebo for 10 days. All patients had access to standard opioid medications. The primary end point was the frequency of predefined adverse events, including cardiovascular events, renal failure or dysfunction, gastroduodenal ulceration, and wound-healing complications. RESULTS: As compared with the group given placebo alone, both the group given parecoxib and valdecoxib and the group given placebo and valdecoxib had a higher proportion of patients with at least one confirmed adverse event (7.4 percent in each of these two groups vs. 4.0 percent in the placebo group; risk ratio for each comparison, 1.9; 95 percent confidence interval, 1.1 to 3.2; P=0.02 for each comparison with the placebo group). In particular, cardiovascular events (including myocardial infarction, cardiac arrest, stroke, and pulmonary embolism) were more frequent among the patients given parecoxib and valdecoxib than among those given placebo (2.0 percent vs. 0.5 percent; risk ratio, 3.7; 95 percent confidence interval, 1.0 to 13.5; P=0.03). CONCLUSIONS: The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,335
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Mangano, C. M., Diamondstone, L. S., Ramsay, J. G., Aggarwal, A., Herskowitz, A., & Mangano, D. T. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00005 · Cited by 1,086
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00889-5 · Cited by 963
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Inflammatory Response to Cardiopulmonary Bypass
Wan, S., LeClerc, J.-L., & Vincent, J.-L. (1997) · Chest · doi:10.1378/chest.112.3.676 · Cited by 888
Aspirin and Mortality from Coronary Bypass Surgery
Mangano, D. T. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020798 · Cited by 674
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Ott, E., Nussmeier, N. A., Duke, P. C., Feneck, R. O., Alston, R. P., Snabes, M. C., Hubbard, R. C., Hsu, P. H., Saidman, L. J., & Mangano, D. T. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00125-9 · Cited by 403
Self-citationCardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Mechanisms of myocardial reperfusion injury
Park, J. L., & Lucchesi, B. R. (1999) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(99)01073-5 · Cited by 337
Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., Melloni, E., Maggiano, N., Zauli, G., & Patrono, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112202999 · Cited by 317
Zimmermann, N., Wenk, A., Kim, U., Kienzle, P., Weber, A.-A., Gams, E., Schrör, K., & Hohlfeld, T. (2003) · Circulation · doi:10.1161/01.cir.0000081770.51929.5a · Cited by 287
Risk of cardiovascular events associated with selective COX-2 inhibitors
Mukherjee, D., Nissen, S. E., & Topol, E. J. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00545-1 · Cited by 208
Cyclooxygenase-2 Inhibitors in Postoperative Pain Management: Current Evidence and Future Directions
Gilron, I., Milne, B., Hong, M. G. L., & Warltier, D. C. (2003) · Anesthesiology · doi:10.1097/00000542-200311000-00029 · Cited by 133
Shear-Induced Platelet Aggregation in Normal Subjects and Stroke Patients
Κωνσταντόπουλος, Κ., Grotta, J. C., Sills, C., Wu, K. K., & Heliums, J. D. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649935 · Cited by 107
Joshi, G. P., Viscusi, E. R., Gan, T. J., Minkowitz, H. S., Cippolle, M., Schuller, R., Cheung, R. Y., & Fort, J. G. (2004) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000093390.94921.4a · Cited by 102
Faymonville, M.-É., Deby-Dupont, G. P., Larbuisson, R., Deby, C. M. T., Bodson, L., Limet, R. R., & Lamy, M. (1986) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)35964-1 · Cited by 101
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00991-1 · Cited by 64
Halt of Celebrex Study Threatens Drug's Future, Other Trials
Couzin, J. (2004) · Science · doi:10.1126/science.306.5705.2170a · Cited by 26
Cited by
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Metadata
- Authors
- Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1081-1091
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139776244
- Cited by
- 1,092
- References
- 24
- FWCI
- 99.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.